Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price Up 6.6%

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX)’s share price shot up 6.6% on Monday . The company traded as high as 1.69 and last traded at 1.69. 3,724,107 shares traded hands during trading, a decline of 3% from the average session volume of 3,849,882 shares. The stock had previously closed at 1.58.

Wall Street Analyst Weigh In

CATX has been the topic of a number of recent analyst reports. Oppenheimer reissued an “outperform” rating and issued a $1.50 price objective (up from $1.20) on shares of Perspective Therapeutics in a research note on Monday, April 1st. B. Riley boosted their price objective on shares of Perspective Therapeutics from $1.20 to $1.70 and gave the stock a “buy” rating in a research note on Tuesday, April 9th.

Perspective Therapeutics Price Performance

The stock has a market capitalization of $997.76 million, a PE ratio of -17.05 and a beta of 1.56. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.07 and a current ratio of 1.07.

Insider Activity

In other news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the firm’s stock in a transaction on Wednesday, March 6th. The shares were purchased at an average cost of 0.95 per share, with a total value of 57,409,487.05. Following the completion of the purchase, the insider now owns 116,773,394 shares of the company’s stock, valued at 110,934,724.30. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 3.52% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Perspective Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CATX. Perkins Capital Management Inc. acquired a new stake in shares of Perspective Therapeutics in the 3rd quarter valued at $731,000. HighTower Advisors LLC acquired a new stake in Perspective Therapeutics in the third quarter worth about $314,000. Taylor & Morgan Wealth Management LLC raised its holdings in Perspective Therapeutics by 8.7% during the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock worth $251,000 after purchasing an additional 50,000 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Perspective Therapeutics during the 3rd quarter valued at about $42,000. Finally, Simplicity Wealth LLC bought a new position in shares of Perspective Therapeutics in the 1st quarter valued at about $40,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.